香港股市 將在 4 小時 53 分鐘 開市

MRK Jan 2023 87.500 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
5.370.00 (0.00%)
市場開市。 截至 02:32PM EDT。
全螢幕
前收市價5.37
開市5.46
買盤5.20
賣出價5.35
拍板87.50
到期日2023-01-20
今日波幅5.25 - 5.50
合同範圍
成交量45
未平倉合約6.29k
  • Insider Monkey

    10 Healthcare Stocks to Watch in Light of Biden’s ‘60 Minutes’ Interview

    In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […]

  • Insider Monkey

    10 Best Diversified Dividend Stocks to Buy Now

    In this article, we discuss 10 best diversified dividend stocks to buy now. You can skip our detailed analysis of best dividend stocks and their returns over the years, and go directly to read 5 Best Diversified Dividend Stocks to Buy Now. In September, the S&P 500 reported its largest percentage drop in 20 years, […]

  • Benzinga

    Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China

    Merck & Co Inc (NYSE: MRK) signed a cooperation framework agreement in China for its COVID-19 antiviral pills, which were co-developed by Ridgeback Therapeutics. The pharma giant has granted Sinopharm exclusive import and distribution rights to Lagevrio (molnupiravir). The companies will also negotiate the feasibility of a technical transfer under the framework so that the drug Molnupiravir could be produced and provided in the Chinese mainland market, Global Times reported. While Pfizer's pills